In The Press

Press

October 22, 2024

Q&A with Bright Pink Founder Lindsay Avner

In the Stanford Under One Umbrella Newsletter, the cancer survivor and activist shares a bright future with Stanford Medicine.

June 5, 2023

Few patients receive recommended genetic testing after cancer diagnosis

A new study finds surprisingly low genetic testing rates for cancer patients who may benefit, especially among Asian, Black and Hispanic patients.

September 17, 2018

Inexpensive testing spurs next of kin to assess their own cancer risk

An online effort coupled with lower costs significantly increased the proportion of cancer patients’ relatives who chose to undergo genetic testing for cancer-associated mutations in Stanford study.

Scientific Articles

January 1, 2019

Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative

In cascade testing, genetic testing for an identified familial pathogenic variant extends to disease-free relatives to allow genetically targeted disease prevention. We evaluated the results of an online initiative in which carriers of 1 of 30 cancer-associated genes, or their first-degree relatives, could offer low-cost testing to at-risk first-degree relatives.

July 3, 2023

Germline Genetic Testing After Cancer Diagnosis

Importance: Germline genetic testing is recommended by practice guidelines for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit from personalized cancer screening and prevention.

March 28, 2019

Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk

Purpose: Multiplex gene panel testing (MGPT) allows for the simultaneous analysis of germline cancer susceptibility genes. This study describes the diagnostic yield and patient experiences of MGPT in diverse populations.